<p>在前面的三个月中，16 位分析师对阿卡迪亚医疗保健公司（NASDAQ: ACHC）发布了评级，呈现出从看涨到看跌的广泛观点。</p>
<p>下表总结了他们最近的评级，提供了过去 30 天情绪变化的概览，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师为阿卡迪亚医疗保健公司设定了 12 个月的价格目标，显示出平均目标为 20.38 美元，最高预估为 30.00 美元，最低预估为 13.00 美元。当前平均价格目标较之前的 25.47 美元下降了 19.98%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768420834_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768420834_0.png"/></p>
<h2>理解分析师评级：全面解析</h2>
<p>通过对最近分析师行动的深入探讨，揭示了阿卡迪亚医疗保健公司在金融专家中的地位。以下总结了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>下调</td>
<td>超越大盘</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>下调</td>
<td>中性</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>下调</td>
<td>同等权重</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>下调</td>
<td>超越大盘</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>下调</td>
<td>中性</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>下调</td>
<td>超配</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>下调</td>
<td>买入</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>下调</td>
<td>买入</td>
<td>$20.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>下调</td>
<td>逊色于大盘</td>
<td>$13.00</td>
<td>$21.50</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Leerink Partners</td>
<td>下调</td>
<td>市场表现</td>
<td>$14.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>下调</td>
<td>超配</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>下调</td>
<td>超越大盘</td>
<td>$22.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>下调</td>
<td>买入</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>下调</td>
<td>买入</td>
<td>$28.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>下调</td>
<td>中性</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>下调</td>
<td>同等权重</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师根据市场条件和公司表现调整他们的建议。无论是 ‘维持’、‘上调’ 还是 ‘下调’ 他们的立场，反映了他们对阿卡迪亚医疗保健公司近期发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 深入评估，分析师赋予定性值，从 ‘超越大盘’ 到 ‘逊色于大盘’。这些评级传达了对阿卡迪亚医疗保健公司相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 深入分析，分析师提供了对阿卡迪亚医疗保健公司股票未来价值的估计。这一分析揭示了分析师预期的变化。</li>
</ul>
<p>理解这些分析师评估与关键财务指标相结合，可以为阿卡迪亚医疗保健公司的市场地位提供有价值的见解。保持信息灵通，做出经过深思熟虑的决策，参考我们的评级表。</p>
<p>随时了解阿卡迪亚医疗保健公司的分析师评级。</p>
<p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
<h2>发现阿卡迪亚医疗保健公司：更深入的了解</h2>
<p>阿卡迪亚医疗保健公司收购和开发行为健康设施。急性住院精神病设施和专业治疗设施为阿卡迪亚在美国的收入贡献了绝大部分。公司的收入来自于为住院精神病和药物滥用护理、门诊精神病护理以及青少年住院治疗提供的服务。</p>
<h3>分析阿卡迪亚医疗保健公司的财务表现</h3>
<p><strong>市值分析：</strong> 公司的市值低于行业平均水平，表明其相对于同行较小。这可能由于多种因素，包括被认为的增长潜力或运营规模。</p>
<p><strong>收入增长：</strong> 阿卡迪亚医疗保健公司在过去三个月中表现出积极的结果。截至 2025 年 9 月 30 日，该公司实现了约 <strong>4.41%</strong> 的稳健收入增长率。这表明公司的收入显著增加。与行业同行相比，该公司的增长率低于医疗保健行业的平均水平。</p>
<p><strong>净利润率：</strong> 阿卡迪亚医疗保健公司的净利润率超越行业基准，达到 <strong>4.26%</strong>。这表明其成本管理高效，财务健康状况良好。</p>
<p><strong>股本回报率（ROE）：</strong> 阿卡迪亚医疗保健公司的 ROE 超越行业基准，达到 <strong>1.17%</strong>。这表明其财务管理稳健，股东权益资本的使用效率高。</p>
<p><strong>资产回报率（ROA）：</strong> 公司的 ROA 表现突出，超过行业平均水平。凭借 <strong>0.57%</strong> 的 ROA，该公司展示了资产的有效利用。</p>
<p><strong>债务管理：</strong> 阿卡迪亚医疗保健公司的债务与股本比率低于行业标准，表明其财务结构稳健，比例为 <strong>0.78</strong>。</p>
<h2>什么是分析师评级？</h2>
<p>评级来自分析师或银行和金融系统内的专家，他们针对特定股票或定义的行业进行报告（通常每季度对每只股票进行一次）。分析师通常从公司电话会议和会议、财务报表以及与重要内部人士的对话中获取信息，以做出决策。</p>
<p>除了他们的评估外，一些分析师还通过提供关键指标的预测，如收益、收入和增长预期，来扩展他们的见解。这些补充信息为交易者提供了进一步的指导。必须认识到，尽管他们是专业人士，分析师仍然是人类，只能根据他们的信念提供预测。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>

阿卡迪亚医疗保健

<p>在过去三个月中，16 位分析师对阿卡迪亚医疗保健公司（NASDAQ:ACHC）进行了评级，显示出从看涨到看跌的情绪混合。12 个月的平均目标价为 20.38 美元，低于 25.47 美元，最高为 30.00 美元，最低为 13.00 美元。分析师们调整了他们的评级，许多人因市场条件变化而下调了目标价。阿卡迪亚医疗保健公司的收入增长率为 4.41%，净利润率为 4.26%，显示出强健的财务健康状况。该公司的债务与股本比率为 0.78，低于行业标准，反映出良好的财务管理</p>

<p>In the preceding three months, 16 analysts have released ratings for Acadia Healthcare Co (NASDAQ: ACHC), presenting a wide array of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>在前面的三个月中，16 位分析师对阿卡迪亚医疗保健公司（NASDAQ: ACHC）发布了评级，呈现出从看涨到看跌的广泛观点。</p>
</div><p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表总结了他们最近的评级，提供了过去 30 天情绪变化的概览，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts have set 12-month price targets for Acadia Healthcare Co, revealing an average target of $20.38, a high estimate of $30.00, and a low estimate of $13.00. Highlighting a 19.98% decrease, the current average has fallen from the previous average price target of $25.47.</p>
<div class="lb-trans"><p>分析师为阿卡迪亚医疗保健公司设定了 12 个月的价格目标，显示出平均目标为 20.38 美元，最高预估为 30.00 美元，最低预估为 13.00 美元。当前平均价格目标较之前的 25.47 美元下降了 19.98%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768420834_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1768420834_0.png"/></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<div class="lb-trans"><h2>理解分析师评级：全面解析</h2>
</div><p>The standing of Acadia Healthcare Co among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过对最近分析师行动的深入探讨，揭示了阿卡迪亚医疗保健公司在金融专家中的地位。以下总结了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$13.00</td>
<td>$21.50</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$14.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>下调</td>
<td>超越大盘</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>下调</td>
<td>中性</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>下调</td>
<td>同等权重</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>下调</td>
<td>超越大盘</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>下调</td>
<td>中性</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>下调</td>
<td>超配</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>下调</td>
<td>买入</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>下调</td>
<td>买入</td>
<td>$20.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>下调</td>
<td>逊色于大盘</td>
<td>$13.00</td>
<td>$21.50</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Leerink Partners</td>
<td>下调</td>
<td>市场表现</td>
<td>$14.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>下调</td>
<td>超配</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>下调</td>
<td>超越大盘</td>
<td>$22.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>下调</td>
<td>买入</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>下调</td>
<td>买入</td>
<td>$28.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>下调</td>
<td>中性</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>下调</td>
<td>同等权重</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Acadia Healthcare Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Acadia Healthcare Co's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师根据市场条件和公司表现调整他们的建议。无论是 ‘维持’、‘上调’ 还是 ‘下调’ 他们的立场，反映了他们对阿卡迪亚医疗保健公司近期发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 深入评估，分析师赋予定性值，从 ‘超越大盘’ 到 ‘逊色于大盘’。这些评级传达了对阿卡迪亚医疗保健公司相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 深入分析，分析师提供了对阿卡迪亚医疗保健公司股票未来价值的估计。这一分析揭示了分析师预期的变化。</li>
</ul>
</div><p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Acadia Healthcare Co's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<div class="lb-trans"><p>理解这些分析师评估与关键财务指标相结合，可以为阿卡迪亚医疗保健公司的市场地位提供有价值的见解。保持信息灵通，做出经过深思熟虑的决策，参考我们的评级表。</p>
</div><p>Stay up to date on Acadia Healthcare Co analyst ratings.</p>
<div class="lb-trans"><p>随时了解阿卡迪亚医疗保健公司的分析师评级。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
</div><h2>Discovering Acadia Healthcare Co: A Closer Look</h2>
<div class="lb-trans"><h2>发现阿卡迪亚医疗保健公司：更深入的了解</h2>
</div><p>Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.</p>
<div class="lb-trans"><p>阿卡迪亚医疗保健公司收购和开发行为健康设施。急性住院精神病设施和专业治疗设施为阿卡迪亚在美国的收入贡献了绝大部分。公司的收入来自于为住院精神病和药物滥用护理、门诊精神病护理以及青少年住院治疗提供的服务。</p>
</div><h3>Breaking Down Acadia Healthcare Co's Financial Performance</h3>
<div class="lb-trans"><h3>分析阿卡迪亚医疗保健公司的财务表现</h3>
</div><p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低于行业平均水平，表明其相对于同行较小。这可能由于多种因素，包括被认为的增长潜力或运营规模。</p>
</div><p><strong>Revenue Growth:</strong> Acadia Healthcare Co displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately <strong>4.41%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> 阿卡迪亚医疗保健公司在过去三个月中表现出积极的结果。截至 2025 年 9 月 30 日，该公司实现了约 <strong>4.41%</strong> 的稳健收入增长率。这表明公司的收入显著增加。与行业同行相比，该公司的增长率低于医疗保健行业的平均水平。</p>
</div><p><strong>Net Margin:</strong> Acadia Healthcare Co's net margin excels beyond industry benchmarks, reaching <strong>4.26%</strong>. This signifies efficient cost management and strong financial health.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> 阿卡迪亚医疗保健公司的净利润率超越行业基准，达到 <strong>4.26%</strong>。这表明其成本管理高效，财务健康状况良好。</p>
</div><p><strong>Return on Equity (ROE):</strong> Acadia Healthcare Co's ROE excels beyond industry benchmarks, reaching <strong>1.17%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> 阿卡迪亚医疗保健公司的 ROE 超越行业基准，达到 <strong>1.17%</strong>。这表明其财务管理稳健，股东权益资本的使用效率高。</p>
</div><p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.57%,</strong> the company showcases effective utilization of assets.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> 公司的 ROA 表现突出，超过行业平均水平。凭借 <strong>0.57%</strong> 的 ROA，该公司展示了资产的有效利用。</p>
</div><p><strong>Debt Management:</strong> Acadia Healthcare Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.78</strong>.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> 阿卡迪亚医疗保健公司的债务与股本比率低于行业标准，表明其财务结构稳健，比例为 <strong>0.78</strong>。</p>
</div><h2>What Are Analyst Ratings?</h2>
<div class="lb-trans"><h2>什么是分析师评级？</h2>
</div><p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<div class="lb-trans"><p>评级来自分析师或银行和金融系统内的专家，他们针对特定股票或定义的行业进行报告（通常每季度对每只股票进行一次）。分析师通常从公司电话会议和会议、财务报表以及与重要内部人士的对话中获取信息，以做出决策。</p>
</div><p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<div class="lb-trans"><p>除了他们的评估外，一些分析师还通过提供关键指标的预测，如收益、收入和增长预期，来扩展他们的见解。这些补充信息为交易者提供了进一步的指导。必须认识到，尽管他们是专业人士，分析师仍然是人类，只能根据他们的信念提供预测。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>
</div>

阿卡迪亚医疗保健公司股票：深入分析分析师观点（16 个评级）